首页> 外文期刊>Drug Design, Development and Therapy >Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold
【24h】

Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold

机译:内过氧化物抗疟疾药:基于1,2,4-三恶烷的结构支架的开发,结构多样性和药效学方面

获取原文
           

摘要

Malaria disease continues to be a major health problem worldwide due to the emergence of multidrug-resistant strains of Plasmodium falciparum . In recent days, artemisinin (ART)-based drugs and combination therapies remain the drugs of choice for resistant P. falciparum malaria. However, resistance to ART-based drugs has begun to appear in some parts of the world. Endoperoxide compounds (natural/semisynthetic/synthetic) representing a huge number of antimalarial agents possess a wide structural diversity with a desired antimalarial effectiveness against resistant P. falciparum malaria. The 1,2,4-trioxane ring system lacking the lactone ring that constitutes the most important endoperoxide structural scaffold is believed to be the key pharmacophoric moiety and is primarily responsible for the pharmacodynamic potential of endoperoxide-based antimalarials. Due to this reason, research into endoperoxide, particularly 1,2,4-trioxane-, 1,2,4-trioxolane- and 1,2,4,5-teraoxane-based scaffolds, has gained significant interest in recent years for developing antimalarial drugs against resistant malaria. In this paper, a comprehensive effort has been made to review the development of endoperoxide antimalarials from traditional antimalarial leads (natural/semisynthetic) and structural diversity of endoperoxide molecules derived from 1,2,4-trioxane-, 1,2,4-trioxolane- and 1,2,4,5-teraoxane-based structural scaffolds, including their chimeric (hybrid) molecules, which are newer and potent antimalarial agents.
机译:由于恶性疟原虫的多药耐药菌株的出现,疟疾仍然是世界范围内的主要健康问题。近年来,基于青蒿素(ART)的药物和联合疗法仍然是抗药性恶性疟原虫疟疾的首选药物。但是,对抗逆转录病毒药物的耐药性已开始在世界某些地区出现。代表大量抗疟疾药物的内过氧化物化合物(天然/半合成/合成的)具有广泛的结构多样性,并具有针对耐药性恶性疟原虫疟疾的所需抗疟疾功效。缺少构成最重要的内过氧化物结构支架的内酯环的1,2,4-三恶烷环系统被认为是关键的药效基团,主要负责基于内过氧化物的抗疟药的药效学潜力。由于这个原因,近年来对内过氧化物,特别是基于1,2,4-三恶烷,1,2,4-三氧戊环和1,2,4,5-四氧杂环己烷的支架的研究引起了广泛的兴趣,以开发抗疟疾的抗疟药。在本文中,已经作出了全面的努力来回顾传统抗疟疾药物(天然/半合成)中内过氧化物抗疟疾药物的发展以及由1,2,4-三恶烷-,1,2,4-三氧戊环衍生的内过氧化物分子的结构多样性-和1,2,4,5-四氧杂环己烷为基础的结构支架,包括其嵌合(杂合)分子,它们是更新且有效的抗疟药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号